Skip to main content

Closed

NBIX: Neurocrine Biosciences, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Strong

Revenue growth+24.8% / yr

Operating margin23.3%

ROIC13.2%

Financially safe

Stretched

Debt / equity0.10×

Interest coverage-271.5×

Current ratio1.87×

Valuation

Unrated

P/E ratio23.7×

Neurocrine Biosciences, Inc.

NBIXNASDAQ Global Select·USD·Closed

Neurocrine Biosciences, Inc.

NBIXNASDAQ·USD·Closed

$166.80

−10.08%

$166.80

−$18.70 (10.08%)

52W Range

70thpctl

Volume

3.74×avg

Mkt Cap

16.77BUSD

P/E

23.7TTM

Div Yield

–ann

52W Range

70thpctl

Volume

3.74×avg

Market Cap

16.77BUSD

P/E Ratio

23.7TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings